Literature DB >> 17112987

Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy.

Ravi G Assomull1, Sanjay K Prasad, Jonathan Lyne, Gillian Smith, Elizabeth D Burman, Mohammed Khan, Mary N Sheppard, Philip A Poole-Wilson, Dudley J Pennell.   

Abstract

OBJECTIVES: We studied the prognostic implications of midwall fibrosis in dilated cardiomyopathy (DCM) in a prospective longitudinal study.
BACKGROUND: Risk stratification of patients with nonischemic DCM in the era of device implantation is problematic. Approximately 30% of patients with DCM have midwall fibrosis as detected by late gadolinium-enhancement (LGE) cardiovascular magnetic resonance (CMR), which may increase susceptibility to arrhythmia and progression of heart failure.
METHODS: Consecutive DCM patients (n = 101) with the presence or absence of midwall fibrosis were followed up prospectively for 658 +/- 355 days for events.
RESULTS: Midwall fibrosis was present in 35% of patients and was associated with a higher rate of the predefined primary combined end point of all-cause death and hospitalization for a cardiovascular event (hazard ratio 3.4, p = 0.01). Multivariate analysis showed midwall fibrosis as the sole significant predictor of death or hospitalization. However, there was no significant difference in all-cause mortality between the 2 groups. Midwall fibrosis also predicted secondary outcome measures of sudden cardiac death (SCD) or ventricular tachycardia (VT) (hazard ratio 5.2, p = 0.03). Midwall fibrosis remained predictive of SCD/VT after correction for baseline differences in left ventricular ejection fraction between the 2 groups.
CONCLUSIONS: In DCM, midwall fibrosis determined by CMR is a predictor of the combined end point of all-cause mortality and cardiovascular hospitalization, which is independent of ventricular remodeling. In addition, midwall fibrosis by CMR predicts SCD/VT. This suggests a potential role for CMR in the risk stratification of patients with DCM, which may have value in determining the need for device therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17112987     DOI: 10.1016/j.jacc.2006.07.049

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  318 in total

1.  Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.

Authors:  Katherine C Wu; Gary Gerstenblith; Eliseo Guallar; Joseph E Marine; Darshan Dalal; Alan Cheng; Eduardo Marbán; João A C Lima; Gordon F Tomaselli; Robert G Weiss
Journal:  Circ Cardiovasc Imaging       Date:  2012-01-20       Impact factor: 7.792

Review 2.  Cardiomyopathies: focus on cardiovascular magnetic resonance.

Authors:  G Quarta; D M Sado; J C Moon
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

3.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  Circulation       Date:  2010-05-17       Impact factor: 29.690

Review 4.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  W Gregory Hundley; David A Bluemke; J Paul Finn; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Vincent B Ho; Michael Jerosch-Herold; Christopher M Kramer; Warren J Manning; Manesh Patel; Gerald M Pohost; Arthur E Stillman; Richard D White; Pamela K Woodard
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

5.  Multiple old myocardial scars and new onset of myocarditis in two young patients presenting with ventricular tachycardias and dilated cardiomyopathy.

Authors:  Anamaria Wolf-Puetz; Matthias Wein; Reinhard Niehues; Marc Horlitz; Malte Kelm; Karin Klingel; Reinhard Kandolf; Rolf Michael Klein
Journal:  Clin Res Cardiol       Date:  2010-12-03       Impact factor: 5.460

Review 6.  The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.

Authors:  Mouaz H Al-Mallah; Mohammad Naseem Shareef
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

Review 7.  Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy.

Authors:  Francisco Leyva; Paul W X Foley
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

Review 8.  Heart failure in patients with normal coronary anatomy: diagnostic algorithm and disease pattern of various etiologies as defined by cardiac MRI.

Authors:  Ralf Wassmuth
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

9.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

Review 10.  Role of cardiac MRI in diabetes.

Authors:  Ravi V Shah; Siddique A Abbasi; Raymond Y Kwong
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.